Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.69 |
| ▸ | PLK4 | O00444 | 4/20 | 0.67 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.63 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.63 |
| ▸ | CCR6 | P51684 | 1/20 | 0.63 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | PLK1 | P53350 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835454 | 1.00 | MEN1 (0.73) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL249651 | 0.88 | MEN1 (0.58) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL249650 | 0.88 | MEN1 (0.58) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL6689356 | 0.87 | PLK4 (0.78) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL3750013 | 0.86 | MAP1LC3B (0.69) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL5727972 | 0.85 | MEN1 (0.66) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL5727968 | 0.85 | MEN1 (0.66) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL29736859 | 0.85 | PLK4 (0.71) | MEN1KMT2ALRRK2PLK4MAP1LC3B | |
| SCHEMBL13081136 | 0.84 | MAPT (0.70) | MEN1KMT2APLK4MAP1LC3BRPS6KA3 | |
| SCHEMBL6857818 | 0.84 | MAPT (0.70) | MEN1KMT2APLK4MAP1LC3BRPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | Acclaim BioMed USA LLC (US) | 2019-10-22 | — | — | US | claimed |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | Acclaim BioMed USA LLC (US) | 2015-02-12 | — | — | US | claimed |
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | Acclaim BioMed USA LLC (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | Acclaim BioMed USA LLC (US) | 2019-10-22 | — | — | US | disclosed |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | Acclaim BioMed USA LLC (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | Acclaim BioMed USA LLC (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | Acclaim BioMed USA LLC (US) | 2015-02-12 | — | — | US | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | MEN1 1169/4885KMT2A 1640/4885LRRK2 715/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | MEN1 1169/4885KMT2A 1640/4885LRRK2 715/4885 |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | MMP1, HES1, COLGALT1 | MEN1 3939/4885KMT2A 3166/4885LRRK2 1222/4885 |
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | MMP1, HES1, COLGALT1 | MEN1 3939/4885KMT2A 3166/4885LRRK2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.